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ABSTRACT
Emergence of drug-resistance to all FDA-approved
antiherpesvirus agents is an increasing concern
in immunocompromised patients. Herpesvirus DNA
polymerase (DNApol) is currently the target of nu-
cleos(t)ide analogue-based therapy. Mutations in
DNApol that confer resistance arose in immunocom-
promised patients infected with herpes simplex virus
1 (HSV-1) and human cytomegalovirus (HCMV), and
to lesser extent in herpes simplex virus 2 (HSV-2),
varicella zoster virus (VZV) and human herpesvirus
6 (HHV-6). In this review, we present distinct drug-
resistant mutational profiles of herpesvirus DNApol.
The impact of specific DNApol amino acid changes
on drug-resistance is discussed. The pattern of
genetic variability related to drug-resistance dif-
fers among the herpesviruses. Two mutational pro-
files appeared: one favoring amino acid changes
in the Palm and Finger domains of DNApol (in -
herpesviruses HSV-1, HSV-2 and VZV), and another
with mutations preferentially in the 3′-5′ exonucle-
ase domain (in -herpesvirus HCMV and HHV-6). The
mutational profile was also related to the class of
compound to which drug-resistance emerged.
INTRODUCTION
Herpesviridae are double-stranded linear DNA viruses that
are responsible for multiple diseases in humans and present
different tropism. The family is divided into ,  and 
subfamilies that contain eight human herpesviruses: herpes
simplex virus 1 and 2 (HSV-1 and HSV-2), and varicella-
zoster virus (VZV) (subfamily ); human cytomegalovirus
(HCMV), human herpesvirus 6 and 7 (HHV-6 and HHV-7)
(subfamily ); Epstein–Barr virus (EBV) and Kaposi’s sar-
coma associated herpesvirus (KSHV) (subfamily  ). Their
large linear genomes range from 125 to 235 kbp (Table 1)
(1,2) and are protected by icosahedral capsids.
Herpesviruses are responsible for a wide variety of dis-
eases and show neural and/or hematogenous dissemina-
tion. HSV-1 and HSV-2 are the causative agents of her-
pes labialis and herpes genitalis, respectively, as well as en-
cephalitis and keratitis (3–7). VZV causes chickenpox and
may reactivate to cause herpes zoster (mainly in elderly
people). HCMV is responsible for infectious mononucle-
osis like syndrome, congenital cytomegalic inclusion body
disease and a variety of manifestations in the transplanted
recipient. These include CMV syndrome, graft infection,
colitis, retinitis, pneumonitis and predisposition to oppor-
tunistic infections (8, 9). HHV-6 is the causative agent
of roseola infantum, and encephalitis in rare cases (10).
The  -herpesviruses are oncogenic, since chronic EBV is
linked to nasopharyngeal carcinoma and Hodgkin and
non-Hodgkin lymphomas (Burkitt’s lymphoma among oth-
ers), besides infectious mononucleosis upon primary infec-
tion. KSHV is responsible for Kaposi’s sarcoma (mostly in
immunocompromised patients) as well as primary effusion
lymphoma and multicentric Castelman’s disease (11–13).
Since the discovery of the nucleoside analogue acyclovir
in the 1970s by G. Elion, a new era in antiviral ther-
apy based on nucleoside derivatives began (14,15). Sev-
eral nucleoside analogues and their prodrugs have been
designed and brought to the market: acyclovir (ACV,
Zovirax R©), ganciclovir (GCV, Cytovene R©, Cymevene R©),
penciclovir (PCV, Denavir R©, Vectavir R©), their prodrugs
[respectively, valacyclovir (Zelitrex R©, Valtrex R©), valganci-
clovir (Valcyte R©), famciclovir (Famvir R©)] and brivudine
(Zonavir R©, Zerpex R©). Brivudine is different from the other
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Table 1. Human herpesviruses (HHV) are divided in 3 subfamilies (,  and  ). Genome size depends on the viral strain for all herpesviruses except
HSV-1 and HSV-2
Subfamilies Herpesvirus name Acronym Genome size (≈kbp)
-herpesvirinae Herpes simplex virus 1 HHV-1/HSV-1 152.2
Herpes simplex virus 2 HHV-2/HSV-2 154.7
Varicella-zoster virus HHV-3/VZV 124.8–125.4
-herpesvirinae Human cytomegalovirus HHV-5/HCMV 229.3–235.6
Herpesvirus 6 HHV-6 159.3–162.1
Herpesvirus 7 HHV-7 144.8–153.0
 -herpesvirinae Epstein–Barr virus HHV-4/EBV 171.8–172.7
Kaposi’s sarcoma associated herpesvirus HHV-8/KSHV 137.5–165.0
antiviral agents since it has a proper sugar ring. Its original-
ity is linked to the bromovinyl moiety present at the C5 po-
sition. Nucleoside analogues are the most frequently used
antiherpesvirus drugs (Figure 1 and Table 2). To be active,
nucleoside analogues necessitate activation to their triphos-
phate form in contrast to CDV and FOS (Figure 2). Foscar-
net (FOS, Foscavir R©), a pyrophosphate analogue, is com-
monly used as second-line treatment for drug-resistant her-
pesvirus strains (4–6,16–23). FOS directly targets the viral
DNApol domain that interacts with the phosphate group
of incoming nucleotides (24). Cidofovir (CDV, Vistide R©),
a nucleotide analogue of dCMP, is recommended only for
multi-drug resistant strains with decreased sensitivity to nu-
cleoside analogues and FOS. ACV, GCV, PCV and their
prodrugs differ from natural nucleosides by the presence
of hydroxyalkyl derivatives instead of a deoxyribose moiety.
Similarly, CDV has no deoxyribose group but, in contrast
to nucleoside analogues, harbors a phosphonate moiety.
Among the many genes expressed during viral replica-
tion, three of them are important in the therapy of her-
pesviruses: thymidine kinase (TK), protein kinase (PK) and
DNApolymerase (DNApol). Herpesvirus TK or PK is nec-
essary for the first phosphorylation step of nucleoside ana-
logue activation. The two next phosphorylation steps are
catalyzed by cellular kinases, leading to nucleoside triphos-
phate analogues that are efficient substrates of the her-
pesvirus DNApol. Incorporation of an activated analogue
inhibits DNA polymerization, interrupting viral genome
replication (Figure 2). Activation by the herpesvirus TK or
PK is not required for CDV since it harbors a phosphonate
moiety and therefore bypasses the first step of phosphoryla-
tion. FOS is a direct inhibitor of herpesvirus DNApol since
it does not require activation.
Long-term exposure to antiviral drugs or suboptimal
doses selects for mutations leading to drug-resistance.
Emergence of drug-resistant herpesvirus strains has in-
creased during the last decades, especially in the im-
munocompromised population (e.g. AIDS and organ and
hematopoietic stem cell transplant patients). Commonly,
single or multiple mutations appear in TK or PK, and to a
lesser extent in DNApol. TKmutations result in lower drug
activation, while DNApol mutations decrease the affinity of
the polymerase for the triphosphate analogues and there-
fore result in weak inhibition of viral DNA synthesis. In re-
cent years, CDV-(CDVR) and FOS-resistant (FOSR) strains
have appeared and themutant viruses have been genotyped,
highlighting the urgent need for new antiviral agents with
broad antiherpesvirus activity (25–29).
In this review, we focus on DNApol (Table 3) and the
emergence of mutations after long-term treatment (for both
clinical and laboratory strains) with antiherpesvirus nu-
cleos(t)ide and pyrophosphate analogues used in antiviral
therapy. The effects of these mutations on the three dimen-
sional structure of the enzyme are discussed. In particular,
we analyzed the distribution of mutations within the func-
tional domains of DNApol for each herpesvirus, depending
on the class of compounds used.
STRUCTURAL FEATURES OF DNA POLYMERASE B
FAMILY
Functional domains of the type B DNA polymerases
DNApol of herpesviruses belongs to the type B family that
comprises, among others, the human DNApol , ,  and
 and the Enterobacteria phage RB69. Type B DNA poly-
merases are composed of functional domains designated
the N-terminal domain, the Finger/Palm/Thumb domains
and the 3′-5′ exonuclease domain (responsible for the proof-
reading activity) (Figure 3). These domains work together
to produce high fidelity replication of the genome. Residues
in the Palm and Finger domains are involved in cataly-
sis and binding of incoming nucleoside triphosphates. The
thumb domain interacts with the primer–template complex.
The architecture of the type B DNApol harbors a 3′-5′
exonuclease domain whose role is to correct misincorpo-
rated nucleotides and to maintain the fidelity and integrity
of the newly formed DNA molecules (30,31). Interestingly,
the HSV-1 DNApol has an extra domain, the pre-NH2-
terminal domain, according to the three dimensional struc-
ture published by Liu et al (32). This domain is required for
efficient viral replication as well as for establishment of la-
tency (as observed experimentally in mice) (33,34). In EBV
DNApol, the pre-NH2-terminal domain is also important
for lytic genome replication (35).
The bacteriophage RB69 DNApol is one of the most
studied at the structural and functional levels, and
there are currently 122 entries in the protein data bank
(http://www.rcsb.org/pdb/results/results.do?outformat=
&qrid=C9789076&tabtoshow=Current) (30,36–40). Al-
though RB69 DNApol lacks the pre-NH2-terminal
domain, it is a good surrogate model for herpesvirus
DNApol, especially regarding structural changes involved
in catalysis and ligand binding (DNA, dNTPs) (36). HSV-1
DNApol structure is also a good structural model for the
other HHVs since the sequence identity is high among
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Figure 1. Structure of the most common nucleos(t)ide analogues used in antiherpesvirus therapy. The antiherpesvirus pharmacopeia includes acyclovir,
ganciclovir, penciclovir and their prodrug products valacyclovir, valganciclovir and famciclovir, as well as brivudine, cidofovir and foscavir.
Table 2. Antiherpesvirus agents and their clinical applications
Antiherpevirus agents Trade names Indication
Route of
administration References
Acyclovir ZoviraxR© HSV-1, HSV-2, VZV Oral, i.v., topical (4–6,14,15,19)
Valacyclovir ValtrexR©, ZelitrexR© HSV-1, HSV-2, VZV Oral (5,6,14,15,21)
Ganciclovir CytoveneR©, CymeveneR© HCMV, HHV-6* Oral, i.v., intravitreal (16,17)
Valganciclovir Valcyte R© HCMV, EBV*, HHV-6* Oral (16,17)
Penciclovir Denavir R©, Vectavir R© HSV-1, HSV-2, VZV Topical (18,21,23)
Famciclovir Famvir R© HSV-1, HSV-2, VZV Oral (18,23)
Brivudine ZostexR©, ZerpexR© HSV-1, VZV Oral (18,20)
Cidofovir VistideR© HCMV, HSV-1, HSV-2 i.v. (14,17,18)
Foscarnet Foscavir R© HCMV, HSV-1, HSV-2,
HHV-6*
i.v. (14,17)
(i.v.: intravenously; *: efficacy under investigation).
the members of the herpesviridae resulting in conserved
protein-folding (32).
Catalytic features responsible for the polymerization activity
The interface between the Finger and Palm domains is im-
portant for the catalytic activity ofDNApol. Two aspartates
in RB69 DNApol, D411 and D623, establish a network of
hydrogen bonds with the  and  phosphates of the incom-
ing nucleoside triphosphate, directly or via magnesium ions
(Figure 4A; active site of RB69 DNApol with incoming
dCTP). In a similar manner, polar residues from the Fin-
ger domain also interact with the three phosphate moieties
of dCTP and the 3′-hydroxyl group of dCTP deoxyribose.
These interactions involve R482, K486, K560 and N564. It
is worth noting that an aromatic residue, Y416, reinforces
the stability of the incoming nucleotide via stacking inter-
actions between its side chain and the sugar ring of the nu-
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Figure 2. Antiviral strategy for inhibition of viral replication by targeting viral DNApol. Nucleoside analogues are active following three step of phospho-
rylation catalyzed by the viral thymidine kinase (TK) and protein kinase (PK), base specific cellular nucleoside monophosphate kinases, and nucleoside
diphosphate kinases. The active triphosphate form is recognized and incorporated in the newly synthesized viral DNA by the herpesvirus DNApol that
inhibits viral replication. The first phosphorylation step is the bottleneck in activating nucleoside analogues. Prodrugs of ACV, GCV and PCV were de-
signed to increase their bioavailability. Cellular esterases release the nucleoside form following drug uptake. It is worth noting that HSV-1 TK and VZV
TK perform two phosphorylation steps to activate BVDU, forming both BVDU-MP and BVDU-DP.
Table 3. The type B DNApol family includes Herpesviridae DNApol, human DNApol ,  and  and the Enterobacteria phage RB69 protein
Formal Name Common name Gene
UniProt
entry
Length
(amino acids)
Human Herpesvirus 1 (HHV-1) Herpes simplex 1 virus (HSV-1) UL30 B2ZUN5 1235
Human Herpesvirus 2 (HHV-2) Herpes simplex 2 virus (HSV-2) UL30 P89453 1240
Human Herpesvirus 3 (HHV-3) VZV ORF28 Q997N0 1194
Human Herpesvirus 4 (HHV-4) EBV BALF5 P03198 1015
Human Herpesvirus 5 (HHV-5) HCMV UL54 P08546 1242
Human Herpesvirus 6 (HHV-6) - U38 P28857 1012
Human Herpesvirus 7 (HHV-7) - U38 P52342 1012
Human Herpesvirus 8 (HHV-8) Kaposi’s sarcoma associated herpesvirus (KSHV) ORF9 Q2HRD0 1012
cleotide. A comparison can be made with the active site
of HSV-1 UL30 whose 3D-structure has been published in
the apo enzyme form (no substrate). Figure 4B represents
the active site of HSV-1 DNApol in the open conforma-
tion without incoming nucleotide. There is a high degree of
sequence identity between residues K786, R789, K811 and
N815 in HSV-1 DNApol and the homologous positions of
R482, K486, K560 and N564 in RB69 DNApol Finger do-
main. Catalytic residues D411 and D623, as well as Y416
are important for dCTP binding in RB69 DNApol (Figure
4A). These residues are conserved in HSV-1 DNApol (ho-
mologous positions D717, D888 and Y722). To be a func-
tional active site, the Finger domain in HSV-1 DNApol un-
dergoes an important movement in order to adapt the envi-
ronment for the incoming dNTP and the template DNA.
Residues in the Finger and Palm domains move closer
to stabilize the complex with the DNA molecule and the
dNTP. Interestingly, among these important residues shap-
ing the active site of HSV-1 DNApol, only N815 was mu-
tated in drug-resistant HSV-1 strains in patients. The other
residues (K786, R789 andK811) were not affected bymuta-
tions (Supplementary Table S1). Indeed, none of the homol-
ogous residues were mutated in other drug-resistant her-
pesviruses, including HSV-2, HCMV and HHV-6.
On the contrary, the homologous position N815 is also
affected in VZV DNApol (i.e. N779S), that conferred
ACVR (41). N815 establishes interactions with the 3′ OH
moiety of the incoming dNTP, which is a critical recogni-
tion step for dNTP incorporation. N815 alterations may af-
fect the recognition of ACV-TP because it lacks a proper
deoxyribose group. In HSV-1 DNApol, several amino
acid changes were identified at position 815 with different
physicochemical properties (apolar residues leucine and va-
line, polar residues tyrosine, glutamate and serine), confirm-
ing the importance of an asparagine residue at this position.
Amino acids other than asparagine could affect the sensitiv-
ity to nucleoside analogues by modifying the chemical en-
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Figure 3. Three dimensional structures of human DNApol ,  and , HSV-1 DNApol and RB69 DNApol. The ternary structure is very similar, with
conserved functional domains in the N-terminus (yellow), Finger (blue), Palm and Thumb (purple and green, respectively) and the Exonuclease (red).
Herpesviruses DNApol possess a pre-N-terminus domain that is not well studied. For human DNApol  and , the model of the 3D-structure was built
using ‘Swiss-Model workspace’ (http://swissmodel.expasy.org/). All the structures were visualized and the pictures generated using PyMolDelano Software.
vironment around position 815 (i.e. shorter side chain, neg-
atively charged residue or hydrophobic amino acid).
Conservation of the finger domain among the type B family
DNA polymerases
The Finger domain is highly conserved in the type B
DNApol family. Figure 4C is a superimposition of sev-
eral DNApol Finger domains (human  and , HSV-1,
VZV, EBV, HCMV and KSHV) showing key residues in
the domain structure and function. The DNApol  posi-
tions Y865, R922, K926, K950, N954 and Y957 are con-
served (aa865, aa922, aa950, aa954 and aa957) or similar
(aa926) in herpesvirus DNApol or in human DNApol ,
and shape the three dimensional structure of the Finger do-
main. Their polar and/or positively charged side chains al-
low establishment of electrostatic or H-bond interactions
with the incoming dNTPs. This domain is critical for catal-
ysis of the polymerase reaction, and the Finger A and Fin-
ger B helices are subject to an important rotation to adopt
an optimal position for substrate recognition (36). A close
view of the humanDNApol  active site shows the same ar-
rangement as the RB69 and HSV-1 DNApols [pdb: 4Q5V;
(42)] (Figure 5). The important residues for catalysis in the
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Figure 4. (A) RB69 DNApol active site complexed to an incoming dCTP. (B) HSV-1 DNApol active site in an open configuration without incoming
nucleotide. (C) Comparison of the Finger domain from human DNApol  (pdb: 4Q5V) and  (model), HSV1 DNApol (pdb: 2VG9), VZV DNApol
(model), EBV DNApol (model), HCMV DNApol (model) and KSHV DNApol (model). Critical amino acids that bind nucleoside triphosphates are
shown in stick representation. Key residues are conserved except at position K926 (in human DNApol ). A lysine (K) is present at this position in human
( and ), and an arginine is found at this position in EBV, HSV-1, VZV, HCMV and KSHV DNApol. The green spheres represent calcium ions (A). All
the structures were visualized and the pictures generated using PyMol Delano Software.
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Figure 5. DNA template binding in the active site of human DNApol .
The Finger (blue) and the Palm domains (green) form the active site to
interact via polar or aromatic residueswith the incoming nucleotide. Pymol
Delano software was used to visualize and generate this figure.
Finger domain of DNApol  are R922, K926, K947, K950
and N954 as well as the dyptich D860/D1004 (homologous
residues of D411/D623 in RB69 and D717/D888 in HSV-
1). Since the Finger domain interacts closely with dNTPs
and therefore with antiherpesvirus drugs, it has been iden-
tified as a preferential site for mutations that confer resis-
tance. Structural similarities among DNApol B type fam-
ily members allow extrapolation to herpesvirus DNApols,
at least for the catalytic process of DNA polymerization,
and to obtain insights into the effects of mutations in drug-
resistant herpesviruses.
Selectivity of antiherpesvirus agents toward the viral DNA
polymerase
Distinct modes of action among the antiherpesvirus agents.
The antiherpesvirus agents presented in this review have a
variety of mechanisms of action leading to the inhibition
of viral DNA replication. The various mechanisms of ac-
tion are due to the chemical and structural heterogeneity
of these drugs, which interact in different ways with the vi-
ral DNApol (Figure 6). ACV triphosphate (ACV-TP) com-
petitively inhibits dGTP binding and is incorporated into
DNA by HSV-1/-2 and VZV DNApol to act as a chain
terminator (Figure 6A). ACV incorporated at the 3′ ex-
tremity of the elongated DNA is also considered a sui-
cide inhibitor because the viral DNApol cannot bypass its
presence through the 3′-5′exonuclease activity (43,44). Al-
though GCV triphosphate (GCV-TP) is structurally related
to ACV-TP, its mode of action is slightly different (Fig-
ure 6A). GCV-TP is both a competitive inhibitor and a
substrate of HCMV DNApol. It is incorporated into viral
DNA but is not considered an obligate chain terminator.
Viral DNA elongation can still be catalyzed, but the pro-
cess stops after one additional nucleotide is incorporated.
Like GCV-TP, PCV triphosphate (PCV-TP) is a competi-
tive inhibitor of theHSV/VZVDNApol and it is a substrate
that allows incorporation of an additional nucleoside (Fig-
ure 6A). The mechanism of action of brivudin distinguishes
it from ACV, GCV and PCV (Figure 6B). The triphosphate
form (BVDU-TP) is a substrate of VZV DNApol and is
a competitive inhibitor with respect to dTTP. However, its
incorporation does not stop elongation of viral DNA but
alters the DNA structure leading to functionally disabled
viral genomes (45,46). Foscavir (FOS) directly targets the
dNTP binding domain of viral DNApol by mimicking py-
rophosphate and preventing efficient binding of the incom-
ing dNTP (Figure 6C). It interacts with residues that rec-
ognize the  and  phosphates of the incoming nucleotide
(47). It impacts viral DNA elongation by aborting the pro-
cess. Cidofovir diphosphate (CDV-DP) is a competitive in-
hibitorwith respect to dCTP and is also a substrate of the vi-
ral DNApol (Figure 6D). No chain termination is observed
unless two successive molecules of CDV-DP are incorpo-
rated into the viral genome. If only one molecule of CDV-
DP is incorporated, then DNA replication continues at a
significantly decreased elongation rate (48).
Inhibitory effects of nucleoside triphosphate analogues on vi-
ral DNA polymerases. The triphosphate forms of antiher-
pesvirus nucleoside analogs are competitive inhibitors of vi-
ral DNApol with respect to the natural nucleoside triphos-
phates dCTP, dGTP and dTTP. The effects of these antiviral
triphosphates were investigated using viral (HSV-1, HSV-2,
VZV and HCMV) and human DNApol  in enzyme as-
says (Table 4) (21,46,49–61). The kinetic parameters were
measured, although values differed depending on the types
of assays used. Sources of variation could be attributed to
the origin of the proteins (extracts of infected cells, recombi-
nant proteins expressed from baculovirus, etc.) and the level
of purity.
The inhibitory constants (KI) of ACV-TP for HSV-1
UL30, HSV-2 UL30, VZV ORF28 and HCMVUL54 were
in the nanomolar range. When tested with human DNApol
, the KI values were in the submicromolar/micromolar
range (0.1–3.8 M). The selectivity (KI human DNApol 
divided by KI viral enzyme) for viral DNApol (HSV-1/2,
HCMV) ranged between 12 and 132 (52,53,56). A KI value
of 990 nM was measured with HSV-1 UL30, but human
DNApol  was not tested in this study and so the selec-
tivity ratio was not calculated (54). Similar KI values were
obtained with GCV-TP when tested with HSV-1, HSV-2
and HCMVDNApol, and the selectivity ratio ranged from
4 to 7.3 due to greater inhibition of human DNApol 
(53,56,62,63).
PCV-TP was tested for inhibition of HSV-1, HSV-2 and
VZV DNApol (21, 58, 64). When activated by phospho-
rylation, the (S)-enantiomeric form is predominantly pro-
duced (>95%) in HSV-infected cells. The inhibitory con-
stants were in the micromolar range (1.6–11 M) while a
KI of 175 Mwas measured for DNApol  (21). Earnshaw
et al. found that the inhibitory effect of PCV-TP on HSV-1
and HSV-2 DNApol activity was 82–121 times weaker than
that of ACV-TP (KI around 70 nM) (21).
BVDU triphosphate (BVDU-TP) inhibitory activity was
assessed on HSV-1, HSV-2, VZV and HCMVDNApol and
compared to human DNApol  (50,51,57,61). Its effect on
DNApol  was in the range of 0.7–3.6 M. The KI of
BVDU-TP forHSV-1 andHSV-2DNApol was 54–250 nM,
while it was 550 nM for VZV DNApol. It is worth not-
ing that BVDU is inactive against HSV-2 despite similar
KI values of BVDU-TP for HSV-1 and -2 DNApol. The
reason is that in HSV-2 infected cells viral TK does not
convert BVDU-MP to BVDU-DP (through TMP kinase-
associated activity) (65–67). BVDU-TP was less potent
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Figure 6. Modes of action of the different antiherpesvirus agents presented in this commentary. The triangles represent nucleotides forming the viral DNA
chain.
Table 4. Kinetic parameters of natural nucleotides and antiherpesvirus agents for HSV-1, HSV-2, VZV and HCMV DNApol and human Pol . KM
represents the concentration of substrate required for 50% enzyme activity, while KI represents the concentration of active nucleoside/nucleotide analogue
required to inhibit DNApol activity by 50%. These constants reflect binding of the inhibitor to the enzyme. References used to build this Table are in
parentheses. KI was not available in some cases, but the IC50 of the drug was published. The (S)- or (R,S)-enantiomeric forms of penciclovir triphosphate
were used in these different studies to measure inhibitory constant values
KM (nM) KI (nM)
DNA polymerases dGTP dCTP dTTP ACV-TP GCV-TP PCV-TP BVDU-TP Foscvavir CDV-DP
HSV-1 UL30 140 (54) 310 (68) 140 (57) 3 (52,53) 30 (61) 3700 (58) 68 (57) 40 (76) 860 (68)
150 (52) 500 (61) 500 (61) 5.1 (58) 33 (53) 85 000 (21) 250 (50) 400 (79)
200 (61) 660 (50) 25 (59) 11 000 (64) IC50 = 750 (51) 600 (73)
235 (53) 70 (21) IC50 = 3000 (72)
570 (21) 990 (54)
HSV-2 UL30 140 (53) 100 (61) 180 (57) 3 (52,53) 46 (53) 3000 (58) 54 (57) 16 000 (75) 1400 (68)
150 (52) 370 (68) 200 (61) 6.7 (58) 6000 (64) 68 (61)
200 (61) 850 (55 70 (21) 5800 (21)
360 (21) 80 (64)
VZV ORF28 640 (49) - 1430 (46) 5.3 (58) - 1600 (64) 550 (46) IC50 = 1000 (49) -
1300 10 (64) 3600 (58) IC50 = 490 (51) IC50 = 180 (51)
IC50 = 37 500 (21)
HCMV UL54 110 (78) 100 (78) 310 (78) 8 (56) 22 (56) - IC50 = 3600 (51) 300 (78) 1200 (62)
240 (62) 230/320 (63) 550 (56) 70/90 (63) 350/450 (63) 6600 (69)
160/260 (63) 260 (62) 600 (61) 85 (62) 400 (80)
440 (105) 570 (56) 932 (74) 4500 (105) 550 (76)
470 (56) 600 (61) 1250 (74)
500 (61) 884 (74) 3500 (62)
IC50 = 9800 (51)
POL 970 (21) 1450 (56) 1200 (57) 96 (56) 80 (60) 175 000 (21) 700 (57) IC50 > 20 000 (194) 51 000 (68)
1200 (52) 4700 (68) 1540 (56) 180 (52) 120 (61) 3600 (50) IC50 = 7700 (51)
1430 (56) 5300 (50) 200 (61) 146 (56) 3600 (61)
3300 (59) IC50 = 21 000 (51)
3800 (21)
when tested with HCMVDNApol, with an IC50 of 3.6 M
(51). KM and KI values for dTTP and BVDU-TP for EBV
DNApol were 13 M and 16.1 M, respectively (50).
Inhibitory effects of the nucleotide analogue cidofovir and
pyrophosphate analogue foscavir on viral DNA polymerases.
The inhibitory effects of CDV-DP on viral DNApol were
investigated for HSV-1 and HSV-2 UL30 as well as for
HCMV UL54 (Table 4) (62,63,68,69). The inhibitory con-
stants were in the range of 0.86 to 6.6 M (for the viral en-
zymes) while the KI for the humanDNApol was about 51
M (68,69). The selectivity for viral DNApol was between
36 and 59. The structure of an oligonucleotide duplex con-
taining CDVwas solved using NMR (70). Incorporation of
CDV was well tolerated and did not dramatically alter the
DNA configuration, which was a common B-type. How-
ever, the stability of the duplex was weaker than a duplex
without incorporated CDV. In contrast, the DNA confor-
mation of an oligonucleotide duplex bearing a ganciclovir
molecule was more altered, switching from the classical B-
type to the A-type nucleic acid that is typical of RNA/RNA
or RNA/DNA duplexes (71).
The inhibitory effects of FOS were investigated for HSV-
1/HSV-2 UL30, VZV ORF28 and HCMV UL54 (Table 4)
(51,62,63,72–80). KI values ranging from 40 to 600 nMwere
measured for HSV-1 UL30 DNApol. In Abele et al., the
IC50 of FOS for VZV DNApol was measured bellow 1 M
(49) while in another study, an IC50 of 180 nMwas observed
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(51). In contrast, KI values ranging from 300 nM to 3.5 M
were obtained with HCMV UL54 DNApol (62,74,76,78).
This difference in inhibitory effects might be due to the as-
say used, its sensitivity or to the quality of the protein pu-
rification. When tested on cellular DNApol , IC50 values
for FOS ranged from 7.7 to 20 M (51).
Structure-activity relationship of the selectivity toward viral
DNA polymerases. Most antiherpesvirus agents exhibit a
preference for viral DNApol, withKI values in the nanomo-
lar range compared to the micromolar range for human
DNApol  (Table 4). This preference is also reflected at the
level of the natural NTP (e.g. dCTP, dGTP and dTTP), sup-
porting the hypothesis that the active site of viral DNApol
harbors few amino acid variations that contribute to sub-
strate selectivity. Figure 7 shows several structural features
that differ between human DNApol  and HSV-1 UL30.
Three distinct residues were identified at positions N862,
K926 and K946 in human DNApol  and A719, R789
and A808 in HSV-1 UL30 (Figure 7A). Residues K926
and K947 in human DNApol (R789/A808 in HSV-1) in-
teract directly with the incoming nucleoside triphosphate
(i.e. dCTP in Figure 7B and C). The amino acid varia-
tions in HSV DNApol (Lys to Arg/Ala) may greatly mod-
ify substrate binding by increasing the side chain volume
[Lys (171A˚) and Arg (225A˚)] or the hydrophobicity of the
residue [percent of buried residue Lys (4.2%) andAla (38%)]
(Figure 7B and C). This suggests better interactions with
the incoming dNTP or a better accommodation of the sub-
strate in the pocket of the active site. The accommodation
of nucleoside and nucleotide analogues with an acyclic part
(instead of a sugar ring) might be favored near residues that
form awider active site. Ala-719 inHSV-1 is conserved in all
herpesviruses except HHV-6 andHHV-7 (Gln574/Gln573).
However, the kinetic parameters of DNApol have not been
studied for these -herpesviruses, and so we cannot draw
conclusions on the impact of the Ala to Gln variation on
substrate selectivity.
FOS binds the DNApol active site differently than nucle-
oside and nucleotide analogues. It competes with the  and
 phosphates of the dNTP, establishing interactions with
polar residues from the Finger domain (Asn, Arg and Lys),
as well as with the catalytic aspartates (Figure 7D). Zahn et
al. solved the structure of RB69 DNApol in complex with
foscavir and acycloGMP (pdb code 3KD5) (47). Foscavir
binds the active site through two groups of interactions. On
one hand, R482, K486, K560 and N564 interact with fos-
cavir through direct hydrogen-bonds or via watermolecules.
On the other hand, the catalytic aspartates D411 and D623
bridge the foscavir molecule via a magnesium ion (Figure
7D).
AMINO ACID CHANGES CONFERRING DRUG-
RESISTANCE PHENOTYPE
A challenging problem in the treatment of herpesvirus in-
fections in immunocompromised patient populations is to
overcome the viruses harboring mutations in TK, PK and
DNApol genes (24). The genetic evolution of the virus aims
to bypass the effects of the drug in order to replicate the vi-
ral genome. Themutations have a variable impact on the en-
zyme and, in the case of DNApol, the mutated position can
affect different domains causing different activities (poly-
merase, 3′-5′ exonuclease). Thus, understanding the distri-
bution of mutations in herpesviruses DNApol is critical not
only for insight into amino acid changes in the polypeptide,
but also for the design of new antiherpetic agents that by-
pass these mutations.
Distribution of mutations in the herpesviridae DNA poly-
merase polypeptide
Effects of mutation distribution on the function of DNApol
domains. Mutations conferring drug-resistance to a wide
family of antiherpesvirus agents have been described in the
last decades (81–88) (Supplementary Data, Table 1). These
include mutations identified in patient samples as well as in
laboratory strains selected under drug-pressure. Among the
eight herpesviruses, data are available for HSV-1, HSV-2,
VZV, HCMV and HHV-6 (Figure 8). In 2009, our labora-
tory initiated the RegaVir translational platform to geno-
type and phenotype herpesvirus strains from patients with
therapeutic failure. This project aimed to advise clinicians
on the therapeutic strategy to treat patients that do not re-
spond to antiviral therapy, and to identify new mutations
leading to drug-resistance. Here, we analyzed the distribu-
tion of mutations per enzyme domain based on amino acid
changes described in the literature or identified by the Re-
gaVir platform. Figure 9 summarizes the distribution of
mutations identified per domain in each herpesvirus. Two
distinct patterns emerged: one group composed of HSV-
1, HSV-2 and VZV with most mutations (69–89%) in the
Palm/Finger/Thumb domains, and a second group com-
posed of HCMV and HHV6A with most mutations (60–
75%) in the 3′-5′ exonuclease (Figure 9). Identification of
additional drug-resistance mutations in HHV6A beyond
the eight identified so far will increase the accuracy of the
mutation profile.
Models of the DNApol of HSV-2, VZV, HCMV and
HHV-6 were built on the basis of HSV-1 DNApol structure
in order to analyze the distribution of the identified muta-
tions (32). A comparison of the Palm and 3′-5′ exonuclease
domains of HSV-1 and of a model of HCMV DNApol is
shown in Figure 10. In each case, the amino acid changes
responsible for drug-resistance are listed and these residues
are represented as a cloud of dots in the 3D-structure. There
are more mutations in the Palm domain of HSV-1 DNApol
than the HCMV counterpart, while the 3′-5′ exonuclease
domain of HCMV contains more mutations than its HSV-1
homologue. These twomutational profilesmay describe two
different mechanisms of drug-resistance, one favoring less
drug incorporation into the viral genome (HSV-1) and the
other activating the proofreading activity of the DNApol to
excise the incorporated nucleoside analogues (HCMV). In-
terestingly, most mutations in VZV DNApol (89.5%) are in
the Palm and Finger domains and confer cross-resistance
to FOS. Notably, VZV DNApol E512K faces the Palm and
Finger domains and its impact on FOS-binding may be sig-
nificant since it is linked to FOSR. In contrast, the HCMV
DNApol bears 50% of mutations in the 3′-5′ exonuclease
domain and has fewer mutations linked to FOSR.
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Figure 7. Structural environment differences between the human DNApol  and HSV-1 UL30 DNApol. (A) Sequence alignment of the Finger domain
fromHSV-1UL30 and humanDNApol . Conserved residues important for polymerase activity are in red and residues that differ are in blue. The asterisks
(*) show conserved positions and single (.) or double (:) dots show residues with similar physico-chemical properties. (B) DNApol  active site in complex
with dCTP and dT, based on RB69 gp43 DNApol structure. (C) HSV-1 UL30 DNApol active site based on RB69 gp43 DNApol structure. (D) FOS and
acyclo-GMP binding the active site of RB69 gp43 DNApol. Magnesium ions are green balls and water molecules are red balls. The black dashed lines
show the polar interactions. All the pictures were generated using PyMol Delano software.
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Figure 8. Amino acid changes in herpesviruses DNApol structure. The locations of the amino acid changes are shown in red. The published structure of
HSV-1 UL30 (pdb: 2GV9) was the model for these 3D-structures of the different Herpesviruses DNApol.
The  -herpesviruses EBV and KSHV are oncogenic and
therefore treatment of acute infections is only proposed in
rare cases. Consequently, the emergence of drug-resistance
mutations in EBV and KSHV has not yet been reported.
Identification of mutations that could arise after long term
exposure to anti-EBV and anti-KSHV agents may be im-
portant. Lytic induction therapy, an innovative approach
for treating  -herpesvirus-associated cancers, aims to reac-
tivate EBV or KSHV from latency and then to inhibit lytic
viral replication using nucleos(t)ide analogues (89–91). Sur-
rogate models such as murine  -herpesvirus 68 (MHV-68)
and herpesvirus Saimiri (HVS) are useful to study drug-
resistance in  -herpesviruses (86). Resistance mutations in
MHV68 and HVS were selected under drug pressure. In
HVS, long term treatment with ACV selected two muta-
tions, S529Y and L631I, in DNApol Palm and Finger do-
mains, respectively (86). These HVS mutant strains were
cross-resistant to GCV, CDV, FOS and adefovir (a drug ap-
proved for treating hepatitis B virus infections that is also
active against HSV-1 and other herpesviruses). The emer-
gence of mutations conferring drug-resistance has to be
considered, and therefore knowledge gathered from surro-
gate models such as MHV-68 and HVS would be crucial.
Mutation distribution associated with nucleoside and
pyrophosphate analogues. Most mutations in HSV-1
DNApol are associated with ACVR, yet some are associ-
ated with different profiles of drug resistance. Mutations
in DNApol conferring resistance to ACV and GCV were
identified that also confer cross-resistance to FOS or
HPMP/PME derivatives. Amino acid changes S724N
and I922N are associated with ACVR+FOSR (92–97).
Interestingly, these amino acids are in the Palm domain,
facing one another, within a 7 A˚-pocket and are very close
to the catalytic aspartates D717/D888 [S724 is 7 A˚ from
D717 and 10 A˚ from D888, while I922 is equidistant (10
A˚)]. Variations at positions V573M, R700M, K960R,
L1007M and I1028T were found in HSV-1 clones selected
with CDV (V573M, R700M and K960R) or HPMPA
(W998L, L1007M and I1028T) in our laboratory. These
positions are widely distributed in the Palm, Thumb and 3′-
5′ exonuclease domains (83,92). Although these mutations
were selected under CDV or HPMPA pressure, there was
no cross-resistance with ACV or FOS. The T821M, Y941H
and R959H amino acid changes in the polymerase subunit
(Finger/Palm/Thumb domains) are linked to ACVR and
FOSR and to CDV sensitivity (83,93).
In HCMV UL54, amino acid changes N495K, D588E,
T700A, V715M, E756D/N/Q and T838A confer only
FOSR, and are widely distributed within the Palm, Fin-
ger and 3′-5′ exonuclease domains. However, variations
at positions 776, 781, 787, 802, 809 and 821 are exclu-
sively in the Finger domain and confer cross-resistance
to GCV and FOS. These observations suggest that vari-
ations linked to FOSR emerge preferentially in the Fin-
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Figure 9. Distribution of the drug-resistance mutations in the Herpesviridae DNApol domains. The total number of mutations is shown for each virus.
ger domain. Most GCVR mutations in UL54 also confer
CDVR, and these are located in the 3′-5′ exonuclease do-
main. Only one amino acid change in the Finger domain,
K805Q, is exclusively associated with CDVR. Multidrug-
resistance (GCVR+FOSR+CDVR) is associated with amino
acid changes V812L, T813S, A834P, G841A and del981-
982. Interestingly, these mutations are located in the Finger
and Palm region of HCMV DNApol.
Mutation distribution associated with HPMP and PME
derivatives. CDV (HPMPC) is the most potent of its class
of antiherpesvirus agents, which are derivatives of (S)-1-[3-
hydroxy-2-(phosphonylmethoxy)-propyl] (HPMP) and [9-
(2-phosphonomethoxy)-ethyl] (PME). Mutations confer-
ring resistance to CDV in HCMV have been isolated from
patients mainly under GCV therapy, but more often were
selected in vitro after long term exposure to the drugs.
PME resistance mutations were isolated from patients in-
fected with HSV-1, HSV-2, HCMV, HHV-6 under FOS
therapy.Most drug-resistant VZV have been isolated in cul-
tured cells (83,86,98–102). Figure 11 summarizes the muta-
tion profiles in DNApol after selection with GCV or FOS
(HCMV) andACV or FOS (HSV, VZV), and whether these
mutations confer cross-resistance toHPMPor PMEderiva-
tives.
In HSV-1 and VZV, mutations were identified in the
Finger, Palm and/or Thumb domains (83,84,92). In HSV-
1 DNApol, variations in residues S724N, E798K, L802F
and R959H were selected under PMEA pressure (83,92),
while Q618H, S724N, E798K and D1070N were identi-
fied in PMEDAPR HSV-1 clones (83,92). Cross-resistance
to PMEA and PMEDAP was associated with these spe-
cific amino acid changes (Figure 11B). Interestingly, S724N
arose using different antiherpesvirus agents (ACV, FOS,
PMEA and PMEADP), indicating a hotspot of genomic
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Figure 10. Comparison of the Palm and 3′-5′ exonuclease domains of HSV-1 andHCMV. Themutated residues are represented as dots in HSV-1 structural
domains (cyan) and in the HCMV homolog domains (green). The amino acid changes were grouped according to the selection drug and listed by virus
using the corresponding font color. Functional domains were visualized and the pictures generated using PyMol Delano software.
variability at this position. Mutations selected under CDV
pressure, V573M, R700M and K960R, were in the 3′-5′ Ex-
onuclease, Palm and Thumb domains, respectively. These
amino acid changes increased the CDVR fold-resistance
from 5.6 to 14 and increased the sensitivity to FOS (hyper-
sensitivity of 0.28- to 0.36-fold), while no cross-resistance
was observed to PMEA and PMEDAP. However, these
three mutations altered the sensitivity to HPMPA (12.5- to
26-fold) (83). Similarly to CDV, the amino acid changes
selected under HPMPA treatment (W998L, L1007M and
I1028T in the Thumb domain) conferred cross-resistance to
CDV (83).
In VZV DNApol, L767S was selected under pressure
with PMEA, and D668Y and M808V were selected under
pressure with PMEDAP. L767S confers cross-resistance to
PMEA, PMEDAP,ACV and PCV (Figure 11D). No amino
acid changes in the N-terminus or the 3′-5′-exonuclease do-
mains of HSV-1 and VZV DNApol arose under selection
with PME derivatives. Interestingly, a distinct pattern of
mutations in HSV-1 UL30 was associated with HPMP and
PME derivatives. Mutations selected with HPMP deriva-
tives were in the Palm, Thumb and 3′-5′ exonuclease do-
mains but not in the Finger domain, while mutations se-
lected with PME derivatives were mostly in the Finger do-
main and some were in the Palm/Thumb domains (Figure
11A and B). In contrast to HSV-1 and VZV, more HCMV
mutations conferring HPMP resistance were in the 3′-5′ ex-
onuclease and Finger domains (Figure 11C). A few muta-
tions were also present in the Palm domain but none in
the Thumb domain. No mutations associated with PME
derivatives in HCMV have been reported.
Most mutations in HHV-6 UL38 gene that confer drug-
resistance were selected under FOS treatment (F292S,
T435R, H507Y, C525S), and few were selected with CDV
(P462S and R798I) (98,103,104). P462S maps to the 3′-
5′ exonuclease domain and R798I is in the Palm domain.
Both P426S and R798I mutations confer cross-resistance to
GCV, but only the homologous P462S substitution was also
identified in GCVR HCMV (i.e. P522S). All four mutations
selected under FOS pressure were in the 3′-5′ exonuclease
domain. T667I, detected in clinical samples, corresponds
to the homologous position V812 in HCMV UL54, which
confers cross-resistance to GCV, FOS and CDV. This posi-
tion is located in the Finger domain of HHV-6 DNApol.
Taken together, these mutation profiles suggest different
mechanisms of drug-resistance forHPMPand PMEderiva-
tives, with HCMV favoring the decrease of DNApol proof-
reading activity (3′-5′ exonuclease domain) while in HSV-1
the binding of the incoming nucleotide analogue is affected.
Effects of drug-resistance amino acid changes on the kinetic
parameters regarding antiherpesvirus agents. The KI val-
ues of recombinant, mutated viral DNApol were measured
to study the effects of amino acid changes on the binding
of antiherpesvirus drugs. These mutations were principally
located in the NH2-terminus, Finger, Palm and Thumb do-
mains. A series of ACVR mutations in HSV-1 UL30 were
characterized by Huang et al (54). Three groups of amino
acid changes were distinguished by their effects on KM of
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Figure 11. Mutations in the 3D-structure of herpesviruses that confer resistance to (A, C and E) HPMP-derivatives or (B and D) PME-derivatives.
The mutations are represented as red dots and the Fingers domain is colored in blue. Panel C mutations: E381K, P401S, N408D/K/S, F412V/C/L/S,
D413E/A/N/Y, V489I, K493Q, L501I/F, T503I, A505V, K513N/R/E, L516R/M, S517F, I521T, P522S/A, C539G/R, D542E, L545S/W, T552S,
Q578H/L, I580T, D588E/N, I726T, E756D, L773V/F, S782L, K805Q, V812L, T813S, A834R and G841A/S.
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ACV-TP, the catalytic constant kcat of ACV-TP or dGTP,
or both KM and kcat. E597K, R700G and R842S altered
ACV-TP binding, changing the wild-type enzyme KM from
0.81 M to 3.8, 5.1 and 3.1 M, respectively. These modifi-
cations increased ACVR 2- to 20-fold. These modifications
did not affect the binding or the efficiency of incorporation
of the natural substrate dGTP.R605V andF891C disturbed
the ACV-TP incorporation rate, slowing the wild-type kcat
of 37 min−1 to 0.61 or 1.8 min−1. These changes in kcat in-
creased ACVR 4- to 10-fold. S724N, Y941H and N961K
altered both KM and kcat of ACV-TP. The apparent affinity
KM changed from 0.81 M to 2.7–4.7 M, and kcat slowed
from 37 min−1 to 9.5–10 min−1. This caused an overall in-
crease in ACVR of 4- to 7-fold. The mutations in this study
are distributed in the NH2-terminus, Palm and Thumb do-
mains of HSV-1 DNApol.
Boivin et al. investigated the effects of W780V in HCMV
UL54 andW781V in HSV-1 UL30, which confer resistance
to FOS, GCV and/or ACV (76). In HSV-1 UL30, W781V
increased the KI from 0.04 to 1.8 M (45-fold), while in
HCMV UL54, W780V increased the KI from 0.55 to 2.7
M (4.9-fold).
Tchesnokov et al. identified L802M (FOSRGCVR) and
K805Q (CDVR) mutations in HCMV UL54 (78). An adja-
cent residue,Q807, was alsomutated (Q807A). These amino
acid changes affected the kinetic parameters of DNApol to-
ward the substrates. L802M and Q807A in the Finger do-
main increased the KI of FOS from 0.30 to 1.9–2.0 M,
leading to a fold-resistance of 6.3–6.7. Interestingly, K805Q
conferred hypersensitivity to FOS, and the KI decreased
from 0.30 to 0.14 M. This amino acid change also con-
ferred resistance to CDV.
Similarly, Cihlar et al. measured the inhibitory constants
of GCV-TP, FOS and CDV-DP for HCMV DNApol mu-
tants K513N and V715M (62). Interestingly, K513N did
not change the KI for the tested compounds and there was
no drug susceptibility correlation between HCMV and en-
zyme. However, KI values increased for CDV-DP (2.4-fold),
GCV-TP (2.9-fold) and FOS (12.8-fold) with V715M com-
pared to wild-type enzyme. V715M altered drug binding
and therefore a drug-sensitivity correlation is possible be-
tween HCMV and the DNApol.
In contrast to mutations in polymerase activity domains,
amino acid changes in the exonuclease domain may not
alter GCV-TP incorporation. Coen et al. investigated the
effects of D301N, F412V and L545S amino acid changes
in the exonuclease domain on the kinetic parameters of
HCMV UL54 DNApol, regarding dGTP and GCV-TP
(105). These amino acid variations had no effect on the
affinity of the enzyme for GCV-TP. The KI values of wild-
type and mutant enzymes were 4.4–5.1 M. The efficiency
of GCV-TP incorporation of the L545Smutant enzymewas
slightly less (kcat = 0.87 min−1) than wild-type enzyme (kcat
of 1.7 min−1).
In summary, mutations have multiple effects on viral
DNApol activity when antiherpesvirus agents are sub-
strates. For instance, mutations modify the binding affinity
(KM) of the nucleos(t)ide analogues or FOS, they impact the
rate of incorporation (kcat) into the viral DNA or they alter
both kinetic parameters. Interestingly, such changes might
not be detectable when the mutations are located in the 3′-5′
exonuclease domain because the polymerization activity is
not affected.
Insights into binding alterations following acquisition of drug-
resistance mutations. The ACV mechanism of action is
distinct from GCV, and this is reflected at the level of drug-
resistance acquisition. ACV is a chain terminator, conse-
quently drug-resistance mutations emerge in residues close
to the - and  - phosphates or around the catalytic aspar-
tates (D717/D888) to bypass the effects of its incorpora-
tion (Figure 12A). Amino acid changes at positions V714,
V715, F716 and A719, which are close to D717, might alter
the network of hydrogen-bonds with ACV-TP. In addition,
alterations in R700, L702, G841, R842 and I922 influence
the binding of ACV-TP, and these form a shell surrounding
D717 (Figure 12A, close view). These amino acid changes
exhibit broad biochemical characteristics, thereby affecting
the catalytic aspartate and ACV-TP binding or incorpora-
tion.
Unlike the mutations observed in UL30 DNApol, only
three amino acid changes in UL54 DNApol were identified
in the shell of residues around the catalytic aspartate D717
(V715M, I726T and T838A). Six residues in the Finger do-
main and four residues that interact with the DNA strand
were changed in UL54 (Figure 12B, inset). The mechanism
of GCV resistance is likely different than ACV in drug-
resistant HSV-1 strains (54). Coen et al. reported the ef-
fects of mutations D301N, F412V and L545S in the 3′-5′ ex-
onuclease domain (105). Their results suggested these mu-
tations allowUL54DNApol to bypass GCV-TP incorpora-
tion and to continue DNA polymerization after n+1 dNTP
addition, leading to GCV in viral DNA strands. Foti et
al. showed that an oligonucleotide duplex containing GCV
has a modified three-dimensional structure compared to a
natural oligonucleotide (71). Therefore, to continue viral
DNA polymerization after GCV incorporation, amino acid
changes are necessary to remodel DNA binding and im-
pair exonuclease activity. This preferential drug-resistance
mechanism might explain the high number of amino acid
changes in the UL54 exonuclease domain, which is in con-
trast to drug-resistant HSV-1 strains that harbor mutations
in the UL30 polymerase domain.
CDV incorporation by HCMV DNApol does not alter
the viral DNA three-dimensional structure (70). However,
the rate ofDNA elongation decreases dramatically, suggest-
ing that DNApol pauses in the presence of incorporated
CDV. Two successive CDV incorporations induce DNA du-
plication arrest, and 3′-5′ exonuclease activity cannot ex-
cise the incorporated CDV (48). The mechanism of CDV-
resistance might involve defects in exonuclease activity to
allow continuation of viral DNA elongation, possibly like
the mechanism proposed for GCV (70,71). Most GCVR-
mutations conferring cross-resistance to CDV are in the ex-
onuclease domain. Position K805 was altered in HCMV
UL54 and conferred resistance to CDV. Although K805 is
in the Finger domain, it faces the 3′-5′ exonuclease domain
with a distance of 6.45 A˚ from residue K493 (K493Q found
in GCVR+CDVR), based on the structure of RB69 gp43.
FOS binding is mediated through interaction with
residues R784/K811 in HCMV UL54 and R785/K811
in HSV-1 UL30 in the Finger domain (Figure 13).
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Figure 12. RB69DNApol complexed to theDNA strand and the incoming dNTP. The amino acid changes (red) identified in (A) ACV/FOS andGCV/FOS
drug-resistantHSV-1 and (B)HCMV.The homologous position inRB69DNApol is in parentheses. The term ‘multi’ refers to a position that can be changed
by different types of amino acids. The catalytic aspartates are shown in magenta. The Finger domain is composed of blue helices, while the Palm domain
is shown in grey and yellow. Insets focus on the incoming dNTP binding to UL30 and UL54 DNApol.
These specific positions are not associated with muta-
tions, but changes in the surrounding positions were
identified [M784T, L782I, W781V, D780N, V813M/A,
N815L/V/Y/E/S/Q/T in HSV-1 UL30 (Figure 13A) and
W780V, V781I, V787L, L802M, A809V, V812L and T813S
in HCMV UL54 (Figure 13B)]. Surprisingly, amino acid
changes in the 3′-5′exonuclease or Palm domains, out-
side the Finger domain, conferred FOS-resistance (N495K,
D588E, T700A, V715M, E756D/N and T838A). The mu-
tationsmight modify the catalytic aspartates or interactions
with the single-strand DNA, allowing new dNTP incorpo-
ration and elongation. Alternatively, distal mutations might
alter the distance between FOS and the interacting residues,
thereby reducing its binding affinity.
NEW DEVELOPMENTS IN ANTIHERPESVIRUS
TREATMENT: WHAT’S THE NEXT STEP?
Several compounds at different stages of drug development
are currently being tested for safety and efficacy against her-
pesvirus infections (Figure 14). These compounds are struc-
turally related or unrelated and target different viral pro-
teins. New strategies involving cellular proteins that are hi-
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Figure 13. Magnified view of the (A) HSV-1 and (B) HCMVDNApol active sites in complex with FOS and acyclo-GMP, based on the three-dimensional
structure of RB69 gp43. Amino acid changes identified in FOS-resistant strains are shown in red.
jacked by the virus are also under investigation. Inhibition
of cellular proteins, including disrupting interactions with
viral proteins or inhibiting enzymatic activity, might be ef-
fective against herpesviruses. In this section, new drugs and
target candidates are described, including those in clinical
trials.
Nucleotidic inhibitors of viral DNA polymerase
Brincidofovir. Brincidofovir (BCV, CMX-001) is a pro-
drug of cidofovir that is effective against several DNA
viruses. Clinical trials are underway to test its efficacy
against several human herpesviruses (106–112). Chimerix,
Inc. conducted a Phase II trial in HCMV seroposi-
tive hematopoietic stem cell transplant recipients to as-
sess BCV safety, tolerability and activity against HCMV
(NCT00942305). This study was completed in January 2012
and demonstrated efficacy of oral BCV against HCMV at
100 mg twice weekly, with gastrointestinal toxicity at 200
mg twice weekly (110). Two Phase III studies started inMay
2015 in HCMV seronegative (NCT02439970) and seroposi-
tive (NCT02439957) kidney allograft recipients to compare
BCV efficacy versus val-GCV. These clinical trials aim to
assess prevention or control of HCMV infection in trans-
plant patients. These programs are active but not yet re-
cruiting patients. BCV is an interesting compound that will
avoid CDV nephrotoxicity since itdisplays a lack of OAT1-
dependant excression in the urine (113). However, its use
will be limited to CDV-sensitive herpesvirus strains. It was
recently reported that BCV resistance mutations in HCMV
UL54 were selected in vitro (114). Three are in the 3′-5′ ex-
onuclease domain (E303G/D, N408K, D413Y) and one is
in the Finger domain (V812L).
Tenofovir. Tenofovir (TFV, PMPA) is a dAMP nucleotide
analogue with activity against HIV and HBV (115). Its
mechanism of action requires phosphorylation by cellular
kinases and incorporation in the viral genome by viral poly-
merase (116–118). In its active diphosphate form, tenofovir-
DP inhibits HSV-1 DNApol with an IC50 of 0.38 g/ml
in the presence of competing dATP (at 3.2 M) (119). A
TFV 1% intravaginal gel is also active against HSV-1 and
HSV-2 infections (119, 120). Clinical trials were completed
to assess the efficacy of TFV in preventing herpes sim-
plex infection. The effect of TFV on genital herpes simplex
virus (HSV-2) shedding was assessed in HIV seronegative
women in a Phase IV study (NCT01448616) (121). Intrav-
aginal TFV gel efficacy was compared to a placebo vagi-
nal gel, oral TFV disoproxil fumarate (TDF, Viread R©) and
oral placebo.Oral TDF failed to prevent lesions or shedding
of HSV-2, whereas vaginal TFV gel reduced HSV-2 shed-
ding by 60%. A Phase III double blind multi-center study
was completed regarding the safety and efficacy of TFV 1%
intravaginal gel in preventing HIV-1 and HSV-2 infection
in sexually active women (NCT01386294). Some protection
against HSV-2 infection in HSV-2 seronegative women was
observed upon pericoital use of TFV 1% intravaginal gel
(122). However, more potent topical antiherpesvirus agents
based on ACV or CDV should be designed and tested in
combination with anti-HIV drugs in a microbicide formu-
lation.
Non-nucleosidic inhibitors of viral DNA polymerase
The use of non-nucleosidic inhibitors of viral DNApol is
an option to address multidrug-resistant infections. Phar-
macia Corp. used high throughput screening to identify a
new class of non-nucleosidic inhibitors of herpesvirus repli-
cation (123,124). One of the most promising compounds, 4-
oxo-dihydroquinoline-3-carboxamide (PNU-183792), was
effective against HCMV, HSV-1, HSV-2, VZV, KSHV and
EBV (when compared to ACV or GCV as reference drugs)
(32,125–128). Liu et al. proposed a model for PNU-183792
activity against HSV-1 that involves stacking the drug be-
tween the primer 3′-end and the template base pairs (32).
However, Q618H in HSV-1 DNApol was selected with
PMEDAP and conferred resistance to PNU-183792 (83).
This demonstrates the difficulty of discovering new an-
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Figure 14. Chemical structure of newly tested compounds with antiherpesvirus activity.
tiherpesvirus drugs because different chemical classes of
compounds might not be effective against multi-drug resis-
tant strains if they target the same viral protein. Although
promising, PNU-183792 has not been developed as an an-
tiherpesvirus drug.
Antiherpesvirus inhibitors under validation process
Helicase–primase inhibitors. The helicase–primase com-
plex required for replication of the viral genome is a po-
tential target of high interest. Two molecules, amenamevir
(ASP2151) and pritelivir (AIC316; BAY-57-1293), have un-
dergone in Phase III and Phase II (NCT01047540) clinical
trials, respectively (129).
Amenamevir was initially developed by Astellas Pharma
Inc. for treating drug-resistant HSV-1 and VZV infections
(130–134). Its development was halted in 2010 due to tox-
icity observed during a Phase I study (NCT00870441).
The results of this Phase I study have not been reported.
Two Phase II studies regarding the effects of amenamevir
on herpes zoster and herpes genitalis were performed in
Japan (NCT00487682, NCT00486200). One-day or 3-day
treatments with amenamevir were effective against episodes
of recurrent genital herpes (135). In 2013, Maruho Co.
Ltd. continued the development of amenamevir and reg-
istered a double-blind and placebo-controlled Phase III
trial for HSV and VZV (NCT01959295, NCT01959841,
NCT02209324). However, patient recruitment has stopped
and no results have been published.
Pritelivir was developed by AiCuris and brought to a
Phase II trial in patients with genital HSV-2 infection
(NCT01047540) (136–138). Some toxicological concerns
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suspended drug development, mainly dermal and hemato-
logical issues in monkeys receiving high doses of pritelivir.
However, this study showed a dose-dependent reduction in
HSV-2 shedding and days with lesions (129, 137). Ame-
namevir and pritelivir have good antiviral activity against
HSV-1 and HSV-2, but toxicity must be overcome for them
to be suitable antiherpesvirus drugs. Less toxic analogues
of these helicase–primase complex inhibitors might unlock
the route for new antiherpesvirus agents that would facili-
tate the management of herpesvirus-associated disease, in-
cluding infections caused by drug-resistant strains.
Protein kinase and terminase inhibitors. UL97 protein ki-
nase and UL89 terminase in HCMV are newly identi-
fied targets (139–146). Maribavir and cyclopropavir (CPV)
inhibit HCMV UL97 protein kinase (147). CPV is also
activated by UL97 protein kinase and cellular GMP ki-
nase to inhibit HCMV DNApol (148–151). Therefore,
CPV has a dual mechanism of action against HCMV
(148,152). HCMV terminase inhibitors are letermovir
(MK-8228; AIC246), BAY-38-4766, 2,5,6-trichloro-1--D-
ribofuranosyl benzimidazole (TCRB) and 2-bromo-5,6-
dichloro-1--D-ribofuranosyl benzimidazole (BDCRB).
Letermovir development is currently ongoing. A Phase
II study was completed, showing its safety and efficacy
against cytomegalovirus reactivation in bonemarrow trans-
planted patients, with an optimal dose at 240 mg per day
(NCT01063829) (153). A Phase III trial is currently recruit-
ing patients (NCT02137772).
Processivity factors binding inhibitors. Accessory proteins
required for herpesvirus DNA replication and interactions
with DNApol might also be targeted. Processivity sub-
units UL42 (HSV-1) and UL44 (HCMV) are associated
with the UL30 and UL54 DNApol, respectively, through
protein–protein interactions with the C-termini (154–157).
In 2004, a study showed that it was possible to inhibit in-
teractions between HSV-1 UL30 and UL42 proteins with
a small molecule, BP5 (158). Similarly, BP5 inhibited asso-
ciation between feline herpesvirus DNApol catalytic sub-
unit and its processivity subunit (159). To our knowledge,
BP5 is not under development. It was reported that ralte-
gravir, an HIV integrase inhibitor, was also active against
HSV-1 by interfering between UL42 and UL30 proteins. A
raltegravir-resistant HSV-1 clone possessed a mutation in
the UL42 gene (V296I) (160). This amino acid change was
in theUL42C-terminal processivity subunit, close to the in-
teraction interface that binds toUL30DNApol. Raltegravir
is also active against HCMV and HSV-2 (160).
Next generation antiherpesvirus inhibitors: which target?
Viral proteins. Proteins associated with viral DNA repli-
cation can be good alternative targets to circumvent
multidrug-resistant strains. Several viral proteins promote
synthesis of NTPs required for viral DNA replication.
The uracil-DNA glycosylase excises uracil residues after
misincorporation of dUMP by viral DNApol. It is espe-
cially important in terminally differentiated neurons be-
cause DNA repair is attenuated compared to undifferenti-
ated dividing-cells (161–164). Its three-dimensional struc-
ture was solved and could be used to design inhibitors
in silico (165). Another enzyme associated with dUMP
metabolism is the dUTP nucleotidohydrolase, which is re-
quired to reduce dUTP misincorporation into viral DNA.
Its inhibition might impair viral replication (166–168). The
ribonucleoside–diphosphate reductase converts ribo-NDP
to deoxy-NDP, and it is involved in viral growth in non-
dividing cells and reactivation from latency. Several stud-
ies qualified this enzyme as a possible target for herpesvirus
replication inhibition (169–171). VZV ORF13 thymidylate
synthase (TS) was recently characterized, and its three-
dimensional structure was solved by Nordlund et al. (pdb
code: 4XSE, 4XSD and 4XSC) (172). They determined that
BVDU monophosphate (BVDU-MP) is a ligand of VZV
TS and suggested rational modification of compounds like
BVDU-MP could have greater affinity for the active site.
The physiological relevance of VZV TS as a therapeutic tar-
get needs further investigation.
The three-dimensional structures of several viral pro-
teases were solved and can be used to design inhibitors in sil-
ico: HCMVUL80 (pdb code: 1WPO and 1IEG) (173–175),
VZV ORF33 (pdb code: 1VZV) (176), HSV-2 UL26 (pdb
code: 1AT3) (177), KSHVORF17 (pdb code: 1FL1, 2PBK,
3NJQ, 4P2T, 4P3T) (178–180) and EBVBVRF2 (pdb code:
1O6E) (181).
Cellular targets. Cellular partners of the herpesvirus life
cycle that could be investigated include those involved in
virus entry, gene transcription, viral protein maturation,
capsid assembly andmaturation or virion egress.Mues et al.
evaluated dynasore, a small-molecule inhibitor of dynamin,
on HSV-1 and HSV-2 life cycle. Dynasore affected virus
entry, trafficking of viral proteins and capsid formation of
HSV-1 and HSV-2 (182). Cheshenko et al. identified a link
between Akt and calcium signaling induced by HSV-1 that
promote virus entry (183). Miltefosine, an anti-leishmania
drug that blocks Akt phosphorylation, was active in vitro
against ACVR HSV-1 by inhibiting HSV-induced calcium
release and virus entry.
Therapeutic vaccines against herpesvirus infection
Therapeutic vaccines are an alternative strategy to the use
of antiviral agents. Two such vaccine candidates are cur-
rently in clinical trials for the treatment of genital herpes,
HerpV (Agenus R©) and GEN-003 (Genocea Bioscience R©)
(184–186). A Phase II clinical trial assessing the efficacy
of HerpV (NCT01687595) showed that a synthetic vaccine
composed of HSV-2 antigenic peptides caused a signifi-
cant decrease in viral load (75%). A booster shot given six
months after the first vaccination was compatible with sus-
tained immunity. A Phase II clinical trial assessing the effi-
cacy of GEN-003 is ongoing and results are expected by late
2016 (NCT01667341). GEN-003 showed promising results
during a Phase II dose optimization study. HSV-2 shedding
(64%) and lesions (65%) were reduced 12 months after vac-
cine completion. No booster shot was tested during the op-
timization process. These therapeutic vaccines had effects
on viral replication and on the clinical aspects of the dis-
eases, with significant reduction of genital lesions. They are
expected to contribute to the management of HSV-2 infec-
tions.
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CONCLUSIONS AND PERSPECTIVES
A distinct mechanism of drug-resistance adopted by HSV-
1, HSV-2 and VZV (-herpesviruses) compared to HCMV
and HHV-6 (-herpesviruses) was determined by analysis
of DNApol mutants and generation of a distribution pro-
file. Insight into the mechanism of drug-resistance is an as-
set in developing new antiviral agents that target the her-
pesvirus DNApol. Accounting for amino acid changes re-
sponsible for drug-resistance provides the basis for new
scaffolds or different chemical modifications.
Since the discovery of nucleoside analogues ACV and
GCV, antiviral research for herpesviruses made a step for-
ward by the design of molecules (i.e. FOS and CDV) that
bypass resistance due to alteration in the viral TK or PK.
Viral TK (encoded by HSV-1, HSV-2 and VZV) and PK
(encoded by HCMV and HHV-6) are required to activate
ACV and GCV, respectively, and so mutations in these
genes generated ACV- or GCV-resistant strains. The py-
rophosphate analogue FOS targets DNApol directly with-
out an activation step, while CDV has a phosphonate moi-
ety that does not require TK or PK activation. However,
CDVR- (selected under GCV therapy) and FOSR-HCMV
strains emerged in immunosuppressed populations over the
last decade, reducing the therapeutic options (27,187–189).
Mutations selected under GCV pressure, for example, led
to cross-resistance to CDV and/or FOS. The consequences
are life-threatening HCMV infections and lack of effec-
tive treatments for managing HCMV-associated diseases.
Therefore, new strategies are needed and new targets must
be discovered to face the health problems caused by drug-
resistant herpesviruses.
The long term success of new nucleoside/nucleotide ana-
logues, or any molecules that target herpesvirus DNApol,
might be diminished due to existing or new mutations in
TK, PK and DNApol. Promising therapeutic strategies for
managing infections with mutli-drug resistant strains are
currently under investigation. Development of therapeutic
vaccines to confer protection againstHSV-1/HSV-2 and de-
crease herpes episodes is also worth effort. An anti-HCMV
vaccine could also be developed for populations suffering
from particular infections such as congenital CMV and
CMV disease in transplant recipients. Several HCMV vac-
cine studies have been initiated and clinical trials performed,
but results were unsatisfactory or the investigations are still
ongoing (190–193).
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